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Background: The AJCC/UICC TNM (tumor, node, metastasis) classification is a
standardized system for the description of anatomical extent and stage grouping of solid
malignant tumors and is regularly updated. We aimed at testing the new 2017 8th edition
of the TNM classification (TNM8) compared to the former 2009 7th edition (TNM7), in
pulmonary squamous cell carcinomas (pSQCC).
Methods: We analyzed a clinico-pathologically well-annotated Western single-center
cohort of 354 consecutive pSQCC, resected 2000–2013, without previous neoadjuvant
therapy. Patients with a clinical history of SQCC of other organs were excluded to
reliably exclude lung metastases. Patients in whom TNM was unclear due to multiple
tumor nodules were excluded. We reevaluated all pathological records and slides and
retrospectively validated pleural invasion for all cases. Raw data of our cohort are
provided as Supplementary Material.
Results: The stage distribution according to TNM7 was as follows: IA (2009): 59
(16.7%), IB: 75 (21.2%), IIA: 71 (20.1%), IIB: 53 (15.0%), IIIA: 79 (22.3%), IIIB: 7
(2.0%), IV: 10 (2.8%). Staging the cases according to TNM8, 7/354 (2.0%) cases were
down-staged, 154 (43.5%) were upstaged; most pronounced between stages IIA(TNM7)
and IIB(TNM8), and IIB(TNM7) and IIIA(TNM8). Both staging systems showed significant
prognostic impact for overall survival, disease free and disease specific survival and time
to recurrence, without significant differences regarding goodness-of-fit criteria (Akaike
Information Criterion and Schwarz Bayesian Criterion).
Conclusion: In conclusion, we show a significant stage migration between tumors
staged using TNM7 and TNM8, without benefit regarding prognostication in our cohort
of primary resected pSQCC.
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INTRODUCTION
The tumor-node-metastasis (TNM) classification aims at
standardizing the description of the anatomical extent of solid
malignant tumors, resulting in the classification of patients into
standardized stage groups for determining their prognosis and
the resulting treatment plan. Effort is made to continuously
refine classification criteria. The current 8th edition of the
TNM classification (TNM8) was published by the Union for
International Cancer Control (UICC) in 2017 (1), as a revision of
the 2009 7th edition (TNM7) (2) and concurrently published by
the American Joint Committee on Cancer (AJCC), with effective
implementation in 2018 (3). The adaptations in TNM8 are based
on recommendations provided by the Staging and Prognostic
Factors Committee (SPFC) of the International Association for
the Study of Lung Cancer (IASLC) published in 2014–2016,
informed on the analysis of large international case collections
with data supplied by 46 institutions in 19 countries (4–7).
Major changes of TNM8 compared to TNM7 applicable to
pulmonary squamous cell carcinomas (pSQCC) are (a) more
refined tumor size cut points in every T-category, using 1 cm
intervals up to the size of 5 cm, (b) the classification of main
bronchus involvement as T2, with removal of the 2 cm distance
from the carina as a limit to separate pT2 and pT3 tumors, (c)
classification of partial as well as total atelectasis as T2, and (d)
regarding diaphragm invasion as a T4 instead of T3 descriptor.
Mediastinal pleural invasion was removed from the criteria of T3
definition due to infrequent use. Furthermore, distant metastases
outside the chest cavity are now subdivided according to number
of metastatic foci.
TNM stage groupings are altered accordingly (7). There are no
changes in the N-category.
Several groups from Asia and North America have validated
the data in mixed cohorts of non-small cell lung cancer,
showing mostly improved prognostication for TNM8 (Table 1)
(8–14). Of note, in a large population based European study
on resected T3N0 NSCLC improved prognostication of TNM8
depended on histological tumor typing (15). SQCC is usually
underrepresented in mixed cohorts (Table 1).
In the present study we aimed to compare the new
TNM8 with the previous TNM7 regarding stage migration and
prognostication in a clinico-pathologically very well-annotated
Swiss single-center pure and large cohort of pSQCC.
PATIENTS AND METHODS
Patient Cohort
The patient cohort consisted of all consecutive patients with
primary resected pSQCC, without neoadjuvant treatment,
resected between January 2000 and December 2013, and
diagnosed at the Institute of Pathology, University of Bern.
The cohort was assembled according to the pathology files, and
subsequently validated by re-checking clinical hospital files and
contacting general practitioners as described elsewhere (16).
In order to include only SQCC originating from the lung
and reliably exclude metastases, patients with previously or
concomitantly diagnosed SQCC of other organ systems were
excluded. We excluded patients who died within 30 days
following surgery (perioperative death) from survival analyses in
order to avoid bias by surgery related short-term mortality. This
retrospective single center study was approved by the Cantonal
Ethics Commission of the Canton of Bern (KEK 200/14), which
waived the requirement for written informed consent. The study
was conducted and is reported according to the REMARK-
guidelines (17).
Histological Tumor Typing Including
Immunohistochemistry
Histological tumor type and histological staging-parameters were
reevaluated for each tumor by two pathologists specializing
in lung pathology (CN, SB) according to the current WHO
classification guidelines, using routine histomorphology and
immunohistochemistry (IHC) (18).
IHC was performed using an automated immunostainer
(Bond III, Leica Biosystems, Muttenz, Switzerland).
Deparaffinized tissue-sections were rehydrated, followed by
antigen retrieval. Endogenous peroxidase activity was blocked
with H2O2 solution (Leica Biosystems). The anti-TTF1 clone
8G7G3/1 (Cell Marque, Rocklin, CA, USA) was used at a dilution
of 1:400. After antigen retrieval performed with Tris-EDTA,
pH 9 for 30min at 95◦C, TTF1 was incubated for 15min at
RT. The polyclonal anti-p40 (Biocare Medical, Biosystems
Switzerland AG, Switzerland) was used at a dilution of 1:100.
After antigen retrieval performed with Tris-EDTA, pH 9.0
for 30min at 100◦C, anti-p40 was incubated for 30min at
RT. Subsequently, samples were incubated with the secondary
antibody using the Bond Polymer Refine Detection Kit with
3-3
′
-diaminobenzidine–DAB as chromogen (Leica Biosystems),
counterstained with hematoxylin, and mounted in Aquatex
(Merck, Darmstadt, Germany).
Staging
For the purpose of this study all tumors were re-staged according
to TNM7 and TNM8 (1, 2).
Information on tumor size and location was re-evaluated,
extracted from the pathology reports and validated using clinical
files and histological slides. Pleural invasion is stage relevant
in tumors up to 3 cm, and was re-assessed for the purpose of
this study in all cases according to current recommendations
by reviewing all histological slides per tumor and if necessary
additionally performing elastica-van-Gieson stains according to
standard protocols, thereby visualizing tumor confined by or
breaking through pleural elastic fibers (19). Lymph-node staging
was validated using the IASLC lymph node map (20).
Clinical Parameters
Clinical parameters were collected as previously reported (21).
In short, data was collected from the patients’ hospital files.
We contacted patients’ general practitioners for additional data
provision, especially regarding progression, survival data and
cause of death.
Time to recurrence (TTR) was defined as the time elapsed
from the day of resection to loco-regional or metastatic
recurrence or disease-specific death. Disease-specific survival
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TABLE 1 | External validation studies of TNM8 vs. TNM7.
Cohort N total
cohort
Improved discrimination
of prognostic groups
using TNM8 vs. TNM7
N SQCC Subanalysis on
SQCC
Country
Jung et al. (12) pN0M0 primary resected
NSCLC (1999–2012)
1,316 No (equal) 385 (29.3%) n.a. Korea—single
institution
Yun et al. (14) ≤IIIB Primary resected
NSCLC (2006–2012)
3,950 yes 1,069 (27.1%) n.a. Korea—single
institution
Chen et al. (9) Primary resected NSCLC
(2006–2015)
2,043 yes 378 (18.8%) n.a. China—single
institution
Sui et al. (10) Primary resected
IA-IIIA (TNM7)
NSCLC (2005–2012)
3,599 yes 1,094 (30.4%) n.a. China—two
institutions
Yang et al. (13) NSCLC (2004–2013) 368,367 (cT)
177,409 (pT)
yes n.a. n.a. North
American—NCDB
Chansky et al. (11) NSCLC* (2000–2012) 612,534 (cT)
182,616 (pT)
yes 25% n.a. North
American—NCDB
Okami et al. (8) Resected NSCLC (2010) 18,973 yes 3,776 (20.1%) n.a. Japan—JJCLCR
Blaauwgeers et al. (15) pT3N0M0 (TNM7) NSCLC
(2010–2013)
683 Depending on tumor type 257 For pT3 due to 2
nodules poorer
prognosis for SQCC
Netherlands—
IKNL and
PALGA
*If surgically treated, only primary resected tumors included.
NSCLC, non-small cell lung cancer; NCDB, National Cancer Data Base; IKNL, Netherlands Comprehensive Cancer Organization; PALGA, Nationwide Network and Registry of
Histopathology and Cytopathology in the Netherlands; JJCLCR, Japanese Joint Committee of Lung Cancer Registry Database.
(DSS) was measured from the day of resection to disease-specific
death. Patients who died due to unrelated causes or secondary
malignancies were censored at the time of death. Disease-free
survival (DFS) was defined as the time elapsed from the day of
resection to loco-regional or metastatic recurrence or death of
any cause. Overall survival (OS) was assessed from the day of
resection to death of any cause.
Statistical Analysis
IBM SPPS Statistics 24 (IBM Corporation, Armonk, USA) was
used for analysis. Group comparisons were performed using
crosstabs, Chi2-tests and Fisher’s exact tests, where appropriate.
Kaplan-Meier curves and log-rank tests were calculated for
univariate survival analysis. Cox regression analysis was used for
multivariate analysis. The significance level for all statistical tests
was set at 0.05.
The Akaike Information Criterion (AIC) and Schwarz
Bayesian Information Criterion (SBC) were used for comparison
of the goodness-of-fit between TNM7 and TNM8. Both methods
adjust the −2 log likelihood statistics for the number of
parameters in themodel and number of observations used. Lower
values of AIC and SBC indicate superior model fit with the “best”
model showing the lowest values for both.
RESULTS
Patient Cohort
The initial cohort included 385 patients. Twenty-three cases
without clear morphological diagnostic criteria for SQCC
(keratinization or intercellular bridges) were excluded: 7 due to
TTF1 positivity, suggestive of adenocarcinoma, 12 due to no or
only weak p40 expression in a screening approach as well as in
whole slide re-evaluation, insufficient for final diagnosis of SQCC
(18), and four cases due to an alternative histological diagnosis
on re-evaluation. Insufficient clinical data and inconsistency
between clinical and pathological staging lead to the exclusion of
eight cases. Finally, 354 cases were available for analysis. All data
on the patient cohort is provided in Table S1.
There were 302 (85.3%) males and 52 (14.7%) females, with a
median age of 69 years at the time of resection (range 43–85).
Survival data were available for finally 256 patients, after
thirteen patients were excluded due to perioperative death.
Survival data up to 5-years after resection was included for
analysis, due to the multimorbidity of the cohort. Median DFS
was 44 months (95% CI= 36–41 months) and median OS was 47
months (95% CI = 38–43 months). Median TTR (data available
for 213 patients) was 47 months (95% CI= 37–43 months).
Of note, 34/88 (38.6%) deaths were unrelated to pSQCC (e.g.,
heart attack, secondary lung adenocarcinoma).
Tumor Characteristics
Median tumor size was 4.5 cm (range 0.8–15 cm). Pleural
invasion was seen in 94/354 (26.6%) patients, with penetration
through the pleural elastic membrane (PL1) in 43 (12.1%), tumor
cells on the pleural surface (PL2) in 28 (7.9%), and invasion of the
parietal pleura (PL3) in 23 (6.5%) patients.
Ipsilateral mediastinal lymph node metastases (pN2) were
detected in 40 (11.3%) patients, hilar-parenchymal lymph node
metastases (pN1) in 110 (31.1%), and 204/354 (57.6%) patients
had no nodal disease (pN0). There was no patient with
contralateral or station 1 lymph nodemetastases (pN3), therefore
no patient classified as UICC stage IIIC. Ten (2.8%) patients had
distant metastases.
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Shifts of the T-Descriptor Between the
TNM7 and TNM8
Detailed data on the frequencies of the T-descriptors according
to TNM7 and TNM8 are provided in Table 2A.
In the new TNM8 classification, the pT1-category was further
subdivided by adding the pT1c-subdivision that is equivalent
regarding size descriptors to the TNM7 pT1b subdivision (>2–
3 cm). Accordingly, all 48 TNM7 pT1b cases were included in
TNM8 pT1c.
The TNM7 pT1a was split between the TNM8 subdivisions
pT1a (≤1 cm) and pT1b (>1–2 cm). Accordingly, 6/32 (18.8%)
of patients from the TNM7 pT1a group remained in the TNM8
pT1a group, 26/32 (81.2%) were staged as TNM8 pT1b.
The size categories were also shifted in the TNM7 pT2a group
(>3–5 cm), now encompassing TNM8 pT2a (>3–4 cm) and
pT2b (>4–5 cm). This resulted in 48/113 (42.5%) TNM7 pT2a
tumors to be up-staged to pT2b. Because the size equivalence
of the TNM7 pT2b subdivision with the TNM8 pT3 category
(>5–7 cm), all TNM7 pT2b tumors were up-staged to pT3.
The only tumors down-staged were from the TNM7 pT3
category (Table 2A). Down-staging of 7/80 (8.8%) TNM7 pT3
cases resulted from the removal of the 2 cm distance from the
TABLE 2 | Comparison of the T-descriptor and Stage distribution as assessed by
TNM7 vs. TNM8 (N = 354).
A pT (TNM7) Total (%)
pT1a pT1b pT2a pT2b pT3 pT4
pT
(TNM8)
pT1a 6 0 0 0 0 0 6 (1.7)
pT1b 26 0 0 0 0 0 26 (7.3)
pT1c 0 48 0 0 0 0 48 (13.6)
pT2a 0 0 65 0 4 0 69 (19.5)
pT2b 0 0 48 0 4 0 52 (14.7)
pT3 0 0 0 54 27 0 81 (22.9)
pT4 0 0 0 0 45 27 72 (20.3)
Total (%) 32
(9.0)
48
(13.6)
113
(31.9)
54
(15.3)
80
(22.6)
27
(7.6)
354 (100)
B Stage (TNM7) Total (%)
IA IB IIA IIB IIIA IIIB IV
Stage
(TNM8)
I A 1 4 0 0 0 0 0 0 4 (1.1)
I A 2 21 0 0 0 0 0 0 21 (5.9)
I A 3 34 0 0 0 0 0 0 34 (9.6)
I B 0 47 0 2 0 0 0 49 (13.8)
II A 0 28 0 1 0 0 0 29 (8.2)
II B 0 0 71 15 4 0 0 90 (25.4)
III A 0 0 0 35 55 0 0 90 (25.4)
III B 0 0 0 0 20 7 0 27 (7.6)
IV A 0 0 0 0 0 0 7 7 (2.0)
IV B 0 0 0 0 0 0 3 3 (0.8)
Total (%) 59
(16.7)
75
(21.2)
71
(20.1)
53
(15.0)
79
(22.3)
7
(2.0)
10
(2.8)
354 (100)
Gray squares depict cases with stage migration.
carina as a limit to separate pT2 and pT3 tumors with main
bronchial involvement. Four tumors were down-staged to TNM8
pT2a (Pat ID 248, 249, 250, 251), another 3 to pT2b (Pat
ID 252, 255, 254; see Table S1). One patient (Pat ID 253, see
Table S1) was down-staged to pT2b due to reclassification of
tumors with total atelectasis from TNM7 pT3 to pT2. Forty-
five/80 (56.3%) TNM7 pT3 category tumors were up-staged to
pT4, now encompassing all tumors over 7 cm diameter.
In summary, pT was significantly up-staged in 147/354
(41.5%) patients and down-staged in 8/354 (2.3%) patient
using TNM8.
Shifts of Tumor-Stage Between TNM7 and
TNM8
Detailed data on the frequencies of UICC-stages according to
TNM7 and TNM8 are provided in Table 2B.
The TNM7 stage IA was subdivided into TNM8 stages IA1
(pT1a), IA2 (pT1b), and IA3 (pT1c). Thus, the stage-distribution
of the 59 N0-M0 tumors among 80 pT1-tumors mirrored the
pT1-subdivisions. Of 75 TNM7 IB tumors, 28 (37.3%) were up-
staged to TNM8 IIA, all of them due to up-staging from TNM7
pT2a to TNM8 pT2b. N1 lymph-node involvement was staged as
IIA in pT1-pT2a tumors and as IIB in pT2b tumors according
to TNM7. In TNM8, any tumors up to pT2b with N1-lymph-
node involvement are staged as IIB. All TNM7 IIA tumors were
thus up-staged to TNM8 IIB. In total, 7/354 (2%) tumors were
down-staged using TNM8 due to down-staging TNM7 pT3 cases
through removal of atelectasis and the 2 cm distance from the
carina as a limit to separate pT2 and pT3 tumors, in node-
negative (TNM7 IIB to IB: Pat. ID 248, 250; to IIA: 254) and
N1-node-positive tumors (TNM7 IIIA to IIB: Pat. ID 249, 251,
252, 253; see Table S1).
Thirty-five/53 (66%) TNM7 IIB tumors were up-staged to
IIIA, 15 N0-tumors due to up-staging TNM7 pT3 to pT4, 20 N1-
tumors due to up-staging TNM7 pT2b to pT3. pT3-N2 tumors
are newly staged as IIIB instead of IIIA. This resulted in up-
staging of 16 tumors, among them 9 were up-staged from pT2b
to TNM8 pT3. Four tumors were size dependently up-staged
from TNM7 pT3 to pT4. In total 20/79 (25.3%) tumors were up-
staged from TNM7 IIIA to TNM8 IIIB. There was no change in
distributions of stages IIIB and IV.
In summary, 154/354 (43.5%) tumors were up-staged and
7/354 (2.0%) down-staged using TNM8.
Survival Analysis and Prognostic Value of
TNM7 and TNM8
Survival data were available for 256 patients. Both staging systems
showed significant prognostic impact regardless if assessment
was conducted using the isolated pT-descriptor (Figure 1) or the
combined UICC stage (Figure 2) for OS (pT-TNM7 p = 0.003,
pT-TNM8 p< 0.001; UICC both p< 0.001), DSS (both TNMs pT
and UICC stage p< 0.001), DFS (both TNMs pT and UICC stage
p< 0.001), and TTR (both TNMs pT and UICC stage p< 0.001).
The Kaplan-Meier curves for TTR are provided as Figure S1.
Although TNM staging showed prognostic significance in
overall analysis, patients with TNM8 UICC stage IIA seemed
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FIGURE 1 | Kaplan-Meier curves showing the overall survival (A,B), disease-specific survival (C,D) and disease-free survival (E,F) by pT-descriptor according to the
seventh and eighth editions of the TNM classification. Comparisons were conducted using a log-rank test. cens, censored.
to have a worse outcome compared to stage IIB, though not
statistically significant, for OS (p = 0.204), DSS (p = 0.066),
and DFS (p = 0.350) (Figure 2). This was mirrored in seemingly
swapped curves in the Kaplan-Meier plots for pT2b- and
pT3-grouped tumors in TNM8 only (Figure 1). The reason for
the discrepancy between TNM7 and TNM8 was the shift of 62%
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FIGURE 2 | Kaplan-Meier curves showing the overall survival (A,B), disease-specific survival (C,D) and disease-free survival (E,F) by stage according to the seventh
and eighth editions of the TNM classification. Comparisons were conducted using a log-rank test. cens, censored.
(32/52) TNM7 pT3 tumors into the TNM8 pT4 category due
to tumor size >7 cm. The TNM7 pT2a group was subdivided
between TNM8 pT2a, showing a prognosis similar to the pT1
categories, and the TNM8 pT2b group with very poor survival.
The poor survival of the 36 patients shifting from TNM7 pT2a
to TNM8 pT2b is not easily explained. In particular, there are no
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differences regarding age, or gender distribution between patients
with TNM8 pT2b and pT3 tumors. Incomplete resections were
more prevalent in the pT3 group (11/51 vs. 1/38, p = 0.026),
as was administration of adjuvant chemotherapy (18/42 vs. 4/33,
p= 0.044).
We used the Akaike Information Criterion (AIC) and the
Schwarz Bayesian Criterion (SBC) as parameters for goodness-
of-fit. The only minimal variance of AIC and SBC denotes no
significant difference in model fit between TNM7 and TNM8 in
our cohort (Table 3).
DISCUSSION
In the present study, we compared the TNM7 system (2) with the
recently published updated TNM8 (1) in a clinico-pathologically
well-annotated, large, Swiss single-center cohort of pSQCC.
Although there was a stagemigration regarding the pT-descriptor
and UICC stage in a significant number of cases, both TNM7 and
TNM8 were prognostically highly significant regarding OS, DSS,
DFS, and TTR. Presumably due to the relatively small cohort size,
we could not demonstrate a statistically significant superiority of
TNM8 comparing the two systems.
The strength of our study is the histologically homogeneous
cohort and the re-validated clinico-pathological parameters for
each patient. Especially in studies including tumors resected over
a long period of time, it must be considered that pathological
workup, histological assessment and diagnostic criteria have
changed during the last years. For the present study, we re-
evaluated all cases according to current WHO 2015-diagnostic
criteria for pSQCC (18).
Additionally, SQCC in the lung may also represent metastases
from extrathoracic primaries. Because risk factors for the
development of SQCC of the lung and oral cavity are virtually
identical, some patients suspected to suffer from pSQCC may
in fact harbor lung-metastases from oral SQCC. As there are no
histological or immunohistochemical differences between SQCC
from different organ systems, care should be administered in
assembling cohorts. In a unique approach, we have assured
true primary pulmonary disease in our cohort by excluding all
patients with synchronous SQCC elsewhere or a history thereof,
thereby reliably excluding possible metastatic disease.
TABLE 3 | Comparison of goodness-of-fit criteria between TNM7 and TNM8.
TNM7 TNM8
OS AIC 890.698 900.33
SBC 905.562 915.194
DFS AIC 1142.98 1159.392
SBC 1159.397 1175.809
DSS AIC 421.923 436.518
SBC 432.628 447.223
TNM7, TNM 7th ed.; TNM8, TNM 8th ed.; AIC, Akaike Information Criterion; SBC,
Schwarz Bayesian Information Criterion; OS, overall survival; DFS, disease free survival;
DSS, disease specific survival.
Even though the database used for developing the
recommendations for TNM8 contained a very large number of
94,708 lung cancer patients, only 30,018 patients had sufficiently
assessable information to settle a pathological pT descriptor,
and data was gained from 35 sources in 16 countries. Half of
the included patients originated from European sources, but no
patients from Switzerland were included (5).
Several validation studies were subsequently published as
summarized in Table 1. We consider our study valuable as
an additional source for elucidating specific aspects of the
TNM-classification in real life, by concentrating on one specific
histological subtype with very consistent pathological and clinical
data that were reassessed and validated for this study.
Our cohort size is comparable to the SQCC content of
previous single-center studies validating TNM8 (9, 12). In
a Chinese cohort of resected NSCLC including only 18.5%
(378/2043) SQCC Chen and co-workers reported a marginally
superior performance of TNM8 regarding prognostication for
the whole cohort (9). A group from South Korea found no
differences between TNM7 and TNM8 assessing the prognostic
value of the pT-descriptor in primary resected node-negative
lung carcinomas without specifying histological type (12). In
a two-center study on a Chinese population, prognostication
using TNM8 was superior to TNM7 in a cohort or primary
resected NSCLC including 1094 SQCC (10). Studies investigating
large national databases validate the TNM8 applicability in
discriminating patient groups (8, 11, 13). To date, none of
the studies validating TNM8 vs. TNM7 reported a subanalysis
for pSQCC.
The evaluation of the National Cancer Data Base (NCDB;
cT: 612,534; pT: 182,616) rendered no significant prognostic
differences between clinically staged IIA (T2b) and IIB (T3)
groups (11). Only 30% of the total cohort was pathologically
staged (N = 182.616), and the overlap between T2b/T3 and
IIA/IIB was lost in this subgroup. The authors speculate that
imprecise radiological tumor measurement may account for
the findings (11). There was also no significant difference in
survival between cIIA and cIIB in a large Japanese Database study
including 18,973 patients (8). An overlap between IIA and IIB or
T2b and T3 groupings was also present in our cohort. Although
both TNM7 and TNM8 were prognostically highly significant
regarding OS, DSS, DFS, and TTR in overall analysis, patients
with TNM8 UICC stage IIB had a worse outcome compared
to stage IIA, mirrored by a worse outcome of patients with
TNM8 pT2b vs. pT3 tumors in TNM8 only, although those
differences were not statistically significant. Our data provide
further validation for splitting TNM7 pT2a tumors into TNM8
pT2a and pT2b, as TNM8 pT2a patients showed a better survival,
but we could not sufficiently explain the poor prognosis of our
TNM8 pT2b group e.g., by differing clinico-pathological patient
characteristics. The finding warrants careful monitoring of the
respective subgroups in subsequent studies.
One limitation of our study is the relatively small cohort size
compared to nationwide databases, which is inherent in the single
center approach and the narrowly defined study population. To
alleviate this concern, we provide full raw data of our cohort to
be available for subsequent meta-analyses (Table S1).
Frontiers in Medicine | www.frontiersin.org 7 September 2019 | Volume 6 | Article 196
Neppl et al. TNM Staging in Pulmonary SQCC
The pivotal studies establishing adjuvant chemotherapy in
NSCLC were based on the 5th and 6th edition of the TNM
classification (TNM5 and TNM6). Even though we show a
significant stage migration regarding pT and tumor stage,
the decision criteria for adjuvant chemotherapy (AC) remain
unaffected. The indication for AC is mainly based on the nodal
stage, which has not been amended since TNM5. The value
of AC in patients with lymph node involvement (N1 and N2
disease) corresponding to stages II and III was confirmed by
meta-analysis after more than two decades, translating into a
4–5% absolute increase in 5-year OS (22). This benefit was
achieved with cisplatin-based doublets, administering at least 300
mg/m2 in 3–4 cycles. Most data support the use of vinorelbine in
combination with cisplatin in the adjuvant setting. The role of
AC in node-negative disease is less evident. A small OS benefit
was observed in a subgroup analysis for node-negative patients
with tumor diameters ≥ 4 cm (23, 24). Importantly though,
tumor stage often presents one inclusion criteria for clinical
studies, and adaptation of stage-defining parameters must be
taken into account.
In conclusion, we show a significant stage migration between
tumors staged using TNM7 and TNM8, without benefit
regarding prognostication in our cohort of pSQCC.
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